Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 127 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Glucose Control Key in Reducing Cancer Risk for People with Type... December 7, 2021 Lack of Evidence for the Use of Telemedicine in the Prevention... September 13, 2021 Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance... July 27, 2022 Study in India Could Make Immunotherapy More Affordable Worldwide November 22, 2022 Load more HOT NEWS Final OS and the Exploratory Analysis of the Outcome with Osimertinib... “Scars are Tattoos with Better Stories” 10 Things I Wish I Knew When I Was First Diagnosed... Partnership in a pandemic: how Credit Suisse delivered an incredible Charity...
